SVB Leerink Analysts Reduce Earnings Estimates for F-star Therapeutics, Inc. (NASDAQ:FSTX)

F-star Therapeutics, Inc. (NASDAQ:FSTXGet Rating) – Analysts at SVB Leerink decreased their Q2 2022 earnings estimates for shares of F-star Therapeutics in a research note issued to investors on Wednesday, May 11th. SVB Leerink analyst D. Graybosch now forecasts that the company will post earnings of ($0.60) per share for the quarter, down from their prior estimate of ($0.59). SVB Leerink also issued estimates for F-star Therapeutics’ FY2022 earnings at ($2.35) EPS, Q3 2023 earnings at ($0.46) EPS, Q4 2023 earnings at ($0.43) EPS, FY2023 earnings at ($1.95) EPS, FY2024 earnings at ($2.47) EPS, FY2025 earnings at ($3.43) EPS and FY2026 earnings at ($3.42) EPS.

A number of other equities research analysts also recently weighed in on FSTX. Zacks Investment Research raised F-star Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, February 8th. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of F-star Therapeutics in a report on Thursday, March 17th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $25.21.

FSTX opened at $2.18 on Friday. F-star Therapeutics has a fifty-two week low of $2.07 and a fifty-two week high of $9.71. The business has a 50-day moving average of $3.21 and a 200-day moving average of $4.28. The company has a debt-to-equity ratio of 0.13, a current ratio of 6.98 and a quick ratio of 6.98. The company has a market capitalization of $47.00 million, a PE ratio of -1.42 and a beta of 1.86.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FSTX. Cubist Systematic Strategies LLC acquired a new stake in F-star Therapeutics in the 4th quarter valued at approximately $29,000. JPMorgan Chase & Co. acquired a new stake in F-star Therapeutics in the 4th quarter valued at approximately $42,000. Envestnet Asset Management Inc. acquired a new stake in F-star Therapeutics in the 1st quarter valued at approximately $48,000. Morgan Stanley grew its holdings in F-star Therapeutics by 65.0% in the 2nd quarter. Morgan Stanley now owns 7,868 shares of the company’s stock valued at $68,000 after buying an additional 3,100 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in F-star Therapeutics in the 3rd quarter valued at approximately $114,000. 51.67% of the stock is currently owned by hedge funds and other institutional investors.

About F-star Therapeutics (Get Rating)

F-star Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.

See Also

Earnings History and Estimates for F-star Therapeutics (NASDAQ:FSTX)

Receive News & Ratings for F-star Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F-star Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.